Please login to the form below

Not currently logged in
Email:
Password:

GSK benefiting from joint R&D

GlaxoSmithKline and Pozen announced on April 17 that the US Food and Drug Administration has approved the migraine medication Treximet
GlaxoSmithKline (GSK) and Pozen announced on April 17 that the US Food and Drug Administration (FDA) has approved the migraine medication Treximet.

Treximet has been developed to treat migraine and could be available in the US market as early as mid-May 2008. Trials into the drug have shown it to be more effective than sumatriptan and naproxen, two existing migraine medications, both of which are components of Treximet.

More than 3,700 migraine patients have been involved in extensive clinical trials that saw Treximet used to treat almost 30,000 migraine attacks.

Dr Stephen Silberstein, professor of neurology and director of the Jefferson Headache Centre at Thomas Jefferson University, said: "The FDA approval of Treximet is good news for migraine patients because clinical trials showed that Treximet produced sustained migraine pain relief for a significant number of patients."

"Migraine patients want their medicine to work early and to continue to provide relief," he added.

GSK has also announced an alliance with Regulus Therapeutics to launch an R&D programme to discover novel microRNA-targeted therapeutics for treating inflammatory conditions, such as rheumatoid arthritis and bowel disease. Regulus will be given a $20m upfront payment as part of the deal.

17th April 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics